Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.

Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.

Abstract: Water-soluble cannabinoid compounds that are agonists of CB1 and CB2 cannabinoid receptors are provided. The compounds are made water-soluble by derivatization of the alkyl side chain and/or the phenolic hydroxyl group of tetrahydrocannabinol. The water-soluble cannabinoids are useful for the treatment of appetite loss, pain, multiple sclerosis, nausea and vomiting, and epilepsy.

Abstract: Compounds of the formula: wherein R, R1 and R4 are defined in the specification, and pharmaceutically acceptable salts, esters and tautomers thereof, having activity at peripheral cannabinoid receptors, commonly designated the CB2 receptor class. The compounds are useful for therapy, especially in the treatment of pain, inflammation and autoimmune disease.

Abstract: Cannabinoid agonists and antagonists are provided for use in the treatment of disorders such as acute and chronic pain, inflammation, loss of appetite, convulsions, multiple sclerosis, nausea and vomiting. The cannabinoid agonists and antagonists contain a sulfonamide moiety incorporated into the cannabinoid side chain, and the side chain itself may be saturated or unsaturated.

Abstract: Compounds of the formula: wherein R, R1 and R4 are defined in the specification, and pharmaceutically acceptable salts, esters and tautomers thereof, having activity at peripheral cannabinoid receptors, commonly designated the CB2 receptor class. The compounds are useful for therapy, especially in the treatment of pain, inflammation and autoimmune disease.

Abstract: Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising: wherein dashed lines independently represent either a single or a double bond, R1 is a lower alkyl, R2 is a lower alkyl, R3 is a lower alkyl or halogen, R4 is a lower alkyl or hydrogen, R5 is a lower alkyl or hydrogen, R6 is a hydrogen, lower alkyl or halogen, and R7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.

Abstract: The invention compounds and methods for the treatment of motor disorders. In particular, the invention provides eicosanoid analogs which are effective in ameliorating motor disorders such as spasticity caused by multiple sclerosis (MS).

Abstract: Analogs of andandamide and arvanil have been found to act preferential at CB1 and AR1 receptors, and at receptors other than CB1 and AR1. The analogs provide analgesic effects in vivo, and are useful in pain management. In addition, the analogs may be used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications. Several of the anandamide and arvanil analogs are more potent than anandamide and arvanil.

Abstract: The invention compounds and methods for the treatment of motor disorders. In particular, the invention provides eicosanoid analogs which are effective in ameliorating motor disorders such as spasticity caused by multiple sclerosis (MS).

Abstract: Disclosed are pyrazole derivatives of formula I: Where R1, R2, R3, and R4 are defined as in the specification described. These compounds are antagonists of the brain cannabinoid (CB-1) receptors and could be used as active gradients in pharmaceutical preparations to block or inhibit cannabinoid receptors in mammals.

Abstract: Water-soluble esters of tetrahydrocannabinoids, which are well-suited for administration in therapeutic aqueous formulations, having following general formula: ##STR1## wherein a - - - b designates a 9(10) or a 9(8) double bond, R' is a --(CH.sub.2).sub.n -- linkage group where n is 1-8, and R is a -(CZ.sub.2).sub.n - linkage group where n is 6 or more and Z independently is H or a substituent such as a lower alkyl group, and the pharmaceutically acceptable salts of these compounds.

Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.

Abstract: A method for treating inflammatory bowel disease in a mammal that includes administering to the mammal and effective amount of spiperone or a spiperone derivative or a pharamaceutically acceptable salt thereof.

Abstract: A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

Abstract: A method for suppressing an immune response in a mammal by systemically treating the mammal with an effective amount of buspirone that is capable of inhibiting classic contact hypersensitivity reactions.

Abstract: The present invention involves 7-carboethoxymorphinan-6-one compounds of the formula: ##STR1## These compounds are useful as analgesic and/or narcotic antagonists.

Abstract: Disclosed is the novel analgesic/narcotic antagonist 17-cyclopropylmethyl-3-hydroxy-14-methoxy-7.alpha.-methyl-morphinan-6-one.

Abstract: Disclosed are certain 14-ethoxymorphinan-6-one compounds exhibiting analgesic and, in some cases, mixed analgesic/narcotic antagonist activity.

Abstract: Disclosed are 4,5.alpha.-epoxy-3-hydroxy or methoxy-7-(1-hydroxyalkyl or 1-oxoalkyl)morphinan-6-one compounds characterized by the structural formulae: ##STR1## In the foregoing formulae R is methyl, cyclopropylmethyl, cyclobutylmethyl, propargyl, allyl, dimethylallyl, cis-chloroallyl or furfuryl; R.sub.1 is H or methyl; R.sub.2 is straight or branched chain alkyl of from 1 to 10 carbon atoms, aryl, substituted aryl or arylalkyl, in which the alkyl group contains from 1 to 6 carbon atoms, and R.sub.3 is a straight chain alkyl of 1 to 4 carbon atoms.